Beam Therapeutics (BEAM) Revenue (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Revenue data on file, last reported at $31.7 million in Q1 2026.

• On a quarterly basis, Revenue rose 324.87% year-over-year to $31.7 million in Q1 2026; TTM through Mar 2026 was $164.0 million, a 157.97% increase from a year earlier, with the FY2025 full-year figure at $139.7 million, up 120.01% from the prior year.
• Revenue for Q1 2026 stood at $31.7 million, down from $114.1 million in the prior quarter.
• Over the last five years, Revenue for BEAM reached as high as $316.2 million in Q4 2023 and fell as low as $7.4 million in Q1 2024.
• Historically, Revenue has averaged $39.6 million across 5 years, with a median of $16.7 million in 2022.
• Across the five-year window, Revenue jumped 277433.33% in 2022 and plunged 90.49% in 2024, its largest moves.
• Year by year, Revenue stood at $20.0 million in 2022, then jumped by 1478.04% to $316.2 million in 2023, then plunged by 90.49% to $30.1 million in 2024, then surged by 279.52% to $114.1 million in 2025, then plunged by 72.19% to $31.7 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $31.7 million in Q1 2026, $114.1 million in Q4 2025, and $9.7 million in Q3 2025.